Sowunmi Akintunde, Akano Kazeem, Ayede Adejumoke I, Ntadom Godwin, Fatunmbi Bayo, Aderoyeje Temitope, Adewoye Elsie O
Department of Pharmacology & Therapeutics, University of Ibadan, Ibadan, Nigeria.
Institute for Medical Research and Training, University of Ibadan, Ibadan, Nigeria.
BMC Infect Dis. 2015 Oct 26;15:454. doi: 10.1186/s12879-015-1219-y.
Artemisinin-based combination treatments (ACTs) or intravenous artesunate are used in over 100 countries for uncomplicated or severe falciparum malaria. Although intravenous artesunate may cause delayed haemolytic anaemia, there is little evaluation of the temporal changes in haematocrit following ACTs.
Clinical and parasitological parameters were measured before and following treatment of uncomplicated falciparum malaria in children with artesunate-amodiaquine (AA) or artemether-lumefantrine (AL) over 6-weeks. Changes in haematocrit were characterized in individual patients based on a haematocrit <30 % or ≥30 % before and following treatment. Kinetics of the deficit in haematocrit from <30 % until attainment of ≥30 % were estimated by a non-compartment model.
In 248 of 1180 children eligible for evaluation, common temporal patterns were: no change or increase in haematocrit from ≥ 30 % [50 % of patients], haematocrit >30 % at presentation declining to <30 % within 2 weeks (early monophasic fall) [19 % of patients], and haematocrit <30 % at presentation increasing to ≥ 30 % [23 % of patients]. Haematocrit >30 % at presentation declining to <30 %, 3-5 weeks later (late monophasic fall) occurred in 7 children (3 %). Fall in haematocrit ≥5 units following treatment occurred in 57 children [23 %] between 14 and 28 days after treatment began. Baseline parasitaemia and proportion with > 100,000μL(-1) asexual forms were significantly higher in children with ≥5 units compared to <5 units fall in haematocrit 21 or 28 days after treatment began. Irrespective of pattern, declines in haematocrit deficit from <30 % were mono-exponential, with similar half-times for AA- and AL-treated children (1.32 d versus 1.14 d). Anaemia half-time correlated significantly positively with anaemia recovery time in the same patients (r = 0.55, P < 0.0001). Bland-Altman analysis of 9 or 10 multiples of anaemia half-time and anaemia recovery times showed narrow limit of agreement with insignificant biases (P = 0.19 or 0.63, respectively).
In uncomplicated falciparum malaria, increases or falls in haematocrit are common following ACTs. Falls in haematocrit ≥ 5 units are common and may or may not result in early or late anaemia. In children who recovered from acute falciparum malaria-associated anaemia following ACTs, decline in haematocrit deficit is mono-exponential.
Pan African Clinical Trial Registry PACTR201508001188143 , 3 July 2015; PACTR201508001191898 , 7 July 2015 http://www.pactr.org .
超过100个国家使用以青蒿素为基础的联合疗法(ACTs)或静脉注射青蒿琥酯来治疗非复杂性或重症恶性疟。尽管静脉注射青蒿琥酯可能会导致迟发性溶血性贫血,但对于ACTs治疗后血细胞比容的时间变化评估较少。
在6周内,对使用青蒿琥酯-阿莫地喹(AA)或蒿甲醚-本芴醇(AL)治疗非复杂性恶性疟的儿童,在治疗前后测量其临床和寄生虫学参数。根据治疗前后血细胞比容<30%或≥30%对个体患者的血细胞比容变化进行特征描述。通过非房室模型估计血细胞比容从<30%直至达到≥30%的下降动力学。
在1180名符合评估条件的儿童中,有248名儿童的常见时间模式为:血细胞比容从≥30%无变化或增加[50%的患者],就诊时血细胞比容>30%在2周内降至<30%(早期单相下降)[19%的患者],就诊时血细胞比容<30%升至≥30%[23%的患者]。就诊时血细胞比容>30%在3 - 5周后降至<30%(晚期单相下降)的情况发生在7名儿童(3%)中。治疗后血细胞比容下降≥5个单位在治疗开始后14至28天内发生在57名儿童(23%)中。与治疗开始后21天或28天血细胞比容下降<5个单位的儿童相比,血细胞比容下降≥5个单位的儿童基线寄生虫血症及无性体>100,000μL⁻¹的比例显著更高。无论模式如何,血细胞比容从<30%的下降均为单指数形式,AA治疗组和AL治疗组儿童的半衰期相似(1.32天对1.14天)。同一患者的贫血半衰期与贫血恢复时间显著正相关(r = 0.55,P < 0.0001)。对贫血半衰期和贫血恢复时间的9或10倍进行布兰德-奥特曼分析显示一致性界限狭窄且偏差不显著(分别为P = 0.19或0.63)。
在非复杂性恶性疟中,ACTs治疗后血细胞比容升高或降低很常见。血细胞比容下降≥5个单位很常见,可能会也可能不会导致早期或晚期贫血。在ACTs治疗后从急性恶性疟相关贫血中恢复的儿童中,血细胞比容下降呈单指数形式。
泛非临床试验注册中心PACTR201508001188143,2015年7月3日;PACTR201508001191898,2015年7月7日http://www.pactr.org